Boehringer ax­es biosim­i­lar de­vel­op­ment out­side US; Macro­Gen­ics, Chi­na's Zai Labs join forces to de­vel­op I/O treat­ments

→ Ger­many’s Boehringer has elect­ed to wash its hands off biosim­i­lar de­vel­op­ment out­side the Unit­ed States. The de­ci­sion like­ly comes in re­ac­tion to the painful …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER